Vident Advisory, LLC Vaxcyte, Inc. Transaction History
Vident Advisory, LLC
- $3.97 Trillion
- Q3 2024
A detailed history of Vident Advisory, LLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Vident Advisory, LLC holds 2,172 shares of PCVX stock, worth $184,902. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,172Holding current value
$184,902% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
357Shares Held
127MCall Options Held
748KPut Options Held
418K-
Vanguard Group Inc Valley Forge, PA12MShares$1.02 Billion0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$930 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$846 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$740 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$417 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $5.05B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...